The potential rescheduling of cannabis to Schedule III has been met with a mix of celebration and skepticism within the industry. While many view this as a significant step forward, I find myself in the camp of cautious observers. As someone who has closely followed and written about cannabis policy, I’ve long maintained that Schedule III is less about progress and more about creating a sweet spot for Big Pharma to dominate the cannabis market, leaving smaller players and consumers at a disadvantage.
Low-dose THC beverages typically contain somewhere between 2 and 5 mg of THC per serving.…
A few dozen strangers answered one question, and here's what they told me. Cannabis rarely…
Federal officials admitted under oath at the DEA marijuana rescheduling hearing that the 54-year-old test…
Discover why Donald Trump lost the 2026 midterms, how the hemp and cannabis industries survived…
On October 29, Fox News ran a column by Dr. Marc Siegel, the network’s senior medical…
Is cannabis a miracle cure or a gateway to ruin? We break down the latest…